Group 1: Financial Performance - The company experienced significant growth in both revenue and net profit in the first half of 2016, attributed to the expansion of the consolidated financial statement scope and improved internal management practices [2]. - The company invested CNY 177 million in Chongzhou Second Hospital to enhance its construction, leveraging its strong local brand and reputation [2]. Group 2: Hospital Operations - Ganxi Tumor Hospital has officially commenced operations and is building a solid foundation in brand, business development, and talent, while collaborating with Jiangxi Provincial Tumor Hospital to enhance its local influence [2]. - The company focuses on selecting hospitals that are either restructured or can be restructured, prioritizing those with a minimum of secondary class and clear specialty advantages, as well as a concentrated regional population [2]. Group 3: Future Developments - The company is planning to construct hospitals primarily focused on oncology and high-end obstetrics, including Dalian International Tumor Hospital and Mianyang Aibeier Obstetrics Hospital, while integrating existing hospital teams and attracting external talent [2]. - The company has established a centralized procurement center to enhance its bargaining power and achieve cost reduction and efficiency improvements [3].

Group 1: Company Strategy and Development - The company has established a health strategy centered on medical services since 2013, focusing on oncology diagnosis and treatment, adhering to the "specialized and comprehensive" approach [2] - The company aims to integrate its operations with target hospitals, providing comprehensive support in discipline construction, talent acquisition, and funding [3] Group 2: Competitive Advantages - The company possesses a team of experienced hospital management professionals and has developed a unique hospital management model [3] - The company has a specialized investment team with extensive experience in hospital reform and operations [3] Group 3: Product Development and Sales - The company includes pharmaceuticals, health products, and toothpaste as part of its health strategy, with a focus on traditional Chinese medicine [3] - The company is actively expanding both online and offline sales channels for its unique series of products [3]

编号：2021-01 证券代码：002219 证券简称：*ST 恒康 恒康医疗集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------|------------| | | □特定对象调研 □分析师会议 | | | | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | | | 类别 | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他 | | | | | 参与单位名称 | | 通过"全景·路演天下"网络平台参与公司 | 2020 | 年度网上业 | | 及人员姓名 | 绩说明会的投资 ...

证券代码：002219 证券简称：*ST 恒康 编号：2022-01 恒康医疗集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------------------------|----------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 √业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | 参与单位名称 | | 通过"全景·路演天下"网络平台参与公司 2021 年度网上业 | | 及人员姓名 | 绩说明会的投资者 | | | 时间 2022 | 年 5 月 11 日 | 15:00-17:00 | | | 地点 "全景·路演天下"（ | http://rs.p5w.net ） | | | | | | 上市公司接待人员 姓名 | 先生、财务总监刘军先生、董事会 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥805,193,959.15, representing an increase of 8.18% compared to the same period last year[7] - The net profit attributable to shareholders for Q3 2022 was ¥15,462,621.60, a significant increase of 185.56% year-on-year[7] - Basic earnings per share for Q3 2022 were ¥0.0189, reflecting a growth of 456.60% compared to the previous year[7] - Total operating revenue for the current period reached ¥2,326,660,478.27, an increase from ¥2,224,300,970.63 in the previous period, representing a growth of approximately 4.6%[36] - Net profit for the current period was ¥121,283,831.87, a significant recovery from a net loss of ¥57,174,950.52 in the previous period[38] - Basic earnings per share for the current period improved to ¥0.0344, compared to a loss of ¥0.0317 per share in the previous period[38] - The company's total profit for the current period was ¥147,571,758.68, a recovery from a total loss of ¥36,220,327.39 in the previous period[38] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥5,502,832,413.37, a decrease of 17.75% from the end of the previous year[7] - As of September 30, 2022, total assets amounted to ¥5,502,832,413.37, a decrease from ¥6,690,205,812.98 at the beginning of the year, representing a decline of approximately 17.7%[29] - Current assets decreased to ¥1,767,932,569.64 from ¥3,023,848,238.36, indicating a reduction of about 41.5%[29] - Total liabilities decreased to ¥3,794,910,476.50 from ¥5,104,155,707.98, reflecting a decline of approximately 25.7%[31] - The company's short-term borrowings significantly decreased from ¥1,274,371,644.23 to ¥99,850,000.00, a reduction of about 92.2%[31] - The company's total equity increased to ¥1,707,921,936.87 from ¥1,586,050,105.00, showing an increase of approximately 7.6%[31] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥97,923,313.84, down 53.27% year-on-year[7] - Cash flow from operating activities generated a net amount of ¥97,923,313.84, down from ¥209,549,867.80 in the previous period[42] - Cash inflow from operating activities totaled ¥2,332,736,027.28, compared to ¥2,184,543,218.48 in the previous period, reflecting an increase of approximately 6.8%[42] - Cash outflow from operating activities was ¥2,234,812,713.44, up from ¥1,974,993,350.68 in the previous period, indicating an increase of about 13.1%[42] - The net cash flow from financing activities was -1,037,090,264.24, a significant decrease compared to -43,062,707.58 from the previous period[45] - The net increase in cash and cash equivalents was -1,399,542,385.38, contrasting with an increase of 29,689,974.08 previously[45] - The ending balance of cash and cash equivalents was 591,558,206.67, down from 1,991,100,592.05 at the beginning of the period[45] Shareholder Information - Total number of common shareholders at the end of the reporting period was 32,374[20] - The largest shareholder, Beijing New Mileage Health Industry Group Co., Ltd., holds 25.30% of shares, totaling approximately 825.93 million shares[20] Company Changes - The company changed its name from "Hengkang Medical Group Co., LTD" to "New Journey Health Technology Group Co., LTD" effective September 26, 2022[26] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 3.84%, an increase of 13.39% compared to the previous year[7] - The company received government subsidies totaling ¥6,655,762.71 during the quarter, contributing to its non-operating income[8] - Interest expenses increased by 58.29% to approximately $106.21 million compared to the same period last year[16] - Interest income surged by 1775.60% to approximately $8.28 million due to increased interest from restructured investments[16] - Investment income rose by 237.29% to approximately $11.57 million, attributed to debt forgiveness[16] - Credit impairment losses increased significantly by 2319.25% to approximately $38.91 million, reflecting recoveries from previous disposals[16] - Tax refunds received increased by 367.44% to approximately $2.73 million compared to the previous year[16] - Cash paid for operating activities rose by 31.40% to approximately $388.97 million, driven by restructuring costs[16] - Cash received from the disposal of subsidiaries amounted to approximately $42 million, marking a 100% increase[16] - Cash received from investment activities reached approximately $100 million, reflecting bank wealth management redemptions[16]

Financial Performance - The company's operating revenue for Q1 2022 was ¥698,315,770.31, representing an increase of 8.98% compared to the same period last year[6] - The net profit attributable to shareholders was -¥47,235,805.90, a decline of 102.53% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥29,791,344.38, a decrease of 103.76% compared to the previous year[6] - The net profit for the quarter was ¥2,413,594.74, a significant recovery from a net loss of ¥48,758,930.91 in the same period last year[31] - The net profit attributable to the parent company was CNY 1,193,558.53, a decrease from a net loss of CNY 47,235,805.90 in the previous period[34] - The total comprehensive income attributable to the parent company was CNY 1,193,558.53, compared to a total comprehensive loss of CNY 47,235,805.90 in the prior period[34] - The basic and diluted earnings per share were both CNY 0.0006, a decline from CNY -0.0253 in the previous period[34] Cash Flow and Liquidity - The net cash flow from operating activities was ¥18,991,307.39, an increase of 68.76% year-on-year[6] - The cash inflow from operating activities totaled CNY 734,705,408.71, an increase from CNY 686,002,024.19 year-over-year[39] - The net cash flow from operating activities was CNY 32,049,044.25, up from CNY 18,991,307.39 in the prior year[39] - The net cash flow from investing activities was CNY -87,667,688.29, compared to CNY -60,508,581.39 in the previous period[41] - The net cash flow from financing activities was CNY 19,900,905.55, an increase from CNY 3,803,312.23 year-over-year[41] - The ending cash and cash equivalents balance was CNY 1,955,382,853.56, down from CNY 105,662,590.55 in the previous period[41] - The company reported a net increase in cash and cash equivalents of CNY -35,717,738.49, compared to a decrease of CNY -37,713,962.02 in the prior year[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,690,205,812.98, reflecting a growth of 1.29% from the end of the previous year[6] - The company's total assets increased to ¥6,776,359,687.06, compared to ¥6,690,205,812.98 in the previous period, marking a growth of 1.3%[28] - Total liabilities rose to ¥5,187,895,987.32, up from ¥5,104,155,707.98, indicating an increase of 1.6%[28] - The company's current assets total 3,029,966,838.82 RMB, slightly increasing from 3,023,848,238.36 RMB at the beginning of the year[22] - The cash and cash equivalents amount to 1,998,186,964.55 RMB, down from 2,033,160,168.10 RMB at the beginning of the year[22] - Accounts receivable increased to 616,533,876.71 RMB from 557,668,826.95 RMB[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,976[13] - The largest shareholder, Que Wenbin, holds 25.61% of the shares, totaling 477,639,999 shares[13] - The top ten shareholders include state-owned and private entities, with significant stakes held by Sichuan Industrial Revitalization Development Investment Fund and Northeast Securities[13] - The company reported a total of 475,687,230 shares under pledge, indicating potential liquidity concerns[13] Operational Changes and Risks - The company has entered the execution phase of its restructuring plan after the court's approval on April 22, 2022[21] - The company faces a risk of bankruptcy if the restructuring plan is not successfully executed[21] - The stock is under "delisting risk warning" and continues to be traded under the name "*ST Hengkang"[21] Expenses - Financial expenses increased by 66.51% to ¥36,557,171.98, primarily due to higher interest from acquisition funds and subsidiary borrowings[9] - The company recorded a decrease in non-operating income by 73.09%, amounting to ¥1,363,790.60 in the previous year[9] - The cash paid for the purchase of fixed assets increased by 44.84% to ¥87,827,688.29, indicating a rise in capital expenditures[12] - The company reported a decrease in sales expenses to ¥43,985,875.41 from ¥54,509,945.31, a reduction of 19.4%[31] - Research and development expenses were not specified, but the company continues to invest in innovation[31] Interest Income - The company reported a significant increase in interest income, which rose by 808.53% to ¥1,510,591.01 due to increased interest from restructured investments[9]

Business Model and Strategy - The company reported a significant shift from a single pharmaceutical manufacturing business to a dual-driven "big health" industry model, focusing on both medical services and pharmaceutical manufacturing [28]. - The company is focusing on expanding its services in response to the increasing healthcare demands driven by aging population and chronic diseases [44]. - The management highlighted the ongoing healthcare reforms as both an opportunity and a challenge for the company's future growth [44]. - The company focuses on a dual-driven strategy of medical services and pharmaceutical manufacturing, enhancing its competitive edge in the healthcare industry [52]. - The company aims to strengthen its regional medical center status by enhancing specialty construction and has received various hospital accreditation achievements in 2021 [63]. - The company is focusing on specialized capacity building in hospitals to enhance competitiveness in regional healthcare development [119]. - The company is committed to enhancing the capabilities of county-level medical services and improving the primary healthcare system [49]. - The company plans to add nearly 2,000 new hospital beds within two years, increasing total bed capacity to 10,000, significantly enhancing operational scale and profitability [119]. Financial Performance - The company's operating revenue for 2021 was ¥3,016,070,733.20, representing a 7.49% increase compared to ¥2,805,895,494.80 in 2020 [30]. - The net profit attributable to shareholders for 2021 was -¥371,431,516.93, a significant decline of 610.96% from -¥52,243,830.15 in 2020 [30]. - The net cash flow from operating activities was ¥277,294,763.28, a slight decrease of 2.29% from ¥283,796,318.85 in 2020 [30]. - The basic and diluted earnings per share for 2021 were -¥0.1991, reflecting a 611.07% decrease from -¥0.0280 in 2020 [30]. - Total assets at the end of 2021 were ¥6,690,205,812.98, an increase of 38.78% from ¥4,820,797,979.68 in 2020 [30]. - The company reported a quarterly operating revenue of ¥791,769,762.57 in Q4 2021, with a total annual revenue of ¥3,016,070,733.20 [36]. - The net profit attributable to shareholders in Q4 2021 was -¥312,357,886.43, contributing to the overall annual loss [36]. - The company experienced a significant increase in non-operating income, with government subsidies amounting to ¥10,098,941.29 in 2021 [40]. Governance and Compliance - The company has established a governance structure that complies with regulatory requirements, ensuring effective decision-making and accountability [129]. - The company has conducted three shareholder meetings during the reporting period, adhering to legal and regulatory standards [130]. - The company maintains complete independence from its controlling shareholders in terms of business operations, assets, personnel, and finance, ensuring no competitive relationship or dependency exists [135]. - The company has established a robust internal audit system with dedicated personnel to oversee internal controls, expenses, and asset management [135]. - The company has a comprehensive information disclosure management system to ensure timely and accurate communication with shareholders [135]. - The company has implemented a transparent investor relations management system to facilitate communication with stakeholders [135]. - The company has recognized the need for better management of fixed asset investments, particularly regarding construction projects that have been stalled since 2019 [195]. Restructuring and Future Plans - The company has entered a restructuring plan execution phase after the court approved the plan, but faces bankruptcy risks if the plan is not executed smoothly [7][9]. - The company is currently in the execution phase of its restructuring plan, having reduced the board of directors from 9 to 5 members, with plans to complete the restructuring before holding further board elections [197]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves for the fiscal year [10]. - The company will firmly promote the long-term strategy of health business in 2022, actively responding to the challenges of population aging and imbalanced medical supply [115]. - The company will increase investment in the technical and research capabilities of medical institutions, enhancing the R&D strength of traditional Chinese medicine and the scale advantages of medical institutions [115]. - The company plans to expand the production scale of "Duyiwei" and enhance annual sales revenue, considering integration through external mergers and acquisitions [118]. Human Resources and Management - The total number of employees at the end of the reporting period was 7,622, with 5,158 being technical staff [174]. - The company has a total of 212 retired employees who require financial support [174]. - The company has undergone significant management changes, with multiple resignations and appointments aimed at meeting development needs [146]. - The management team includes experienced professionals with backgrounds in finance, healthcare, and management [150][151]. - The company is addressing human resource risks by focusing on attracting and retaining high-quality medical and management talent [124]. Market and Product Development - The company has over 36 pharmaceutical products, including 8 exclusive products nationwide and 20 products listed in the medical insurance catalog [52]. - The company's main product, "Duyiwei Capsules," has been included in the National Essential Medicines List, which is expected to positively impact market prospects [124]. - The company is exploring new high-end domestic medical services and innovative biopharmaceutical research and market operations [55]. - The company is committed to developing new technologies and products to meet market demands [154]. - Future guidance indicates a focus on strategic acquisitions and partnerships to bolster growth [148]. Risks and Challenges - The company emphasizes the importance of risk awareness among investors regarding future operational plans and profitability forecasts [6]. - The company faces potential risks from policy changes in healthcare reform, which could impact operations [122]. - The company has acknowledged issues with accounts receivable, particularly with a significant amount overdue for more than one year, reflecting insufficient collection efforts [194].

Financial Performance - The company's operating revenue for Q3 2021 was ¥744,304,252.04, a decrease of 0.94% compared to the same period last year[4] - The net profit attributable to shareholders was -¥9,963,674.44, representing a significant decline of 697.40% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥18,072,105.28, down 192.72% from the previous year[4] - The basic earnings per share for the period was -¥0.0053, a decrease of 657.14% compared to the same period last year[4] - Net profit for the current period was -¥57,174,950.52, compared to -¥40,997,680.27 in the previous period, indicating a deeper loss[33] - The company reported a basic and diluted earnings per share of -¥0.0317, compared to -¥0.0263 in the previous period[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,985,347,921.82, an increase of 3.41% compared to the end of the previous year[4] - The total liabilities of the company as of September 30, 2021, were approximately CNY 4.29 billion, an increase from CNY 4.09 billion at the end of 2020, representing a rise of about 4.9%[25] - The total liabilities increased to ¥4,884,685,581.14 from ¥4,662,960,688.48, marking a growth of 4.7%[29] - The total equity attributable to shareholders decreased to ¥74,772,530.44, a decline of 44.14% from the previous year-end[4] - The total equity attributable to shareholders of the parent company decreased to ¥74,772,530.44 from ¥133,846,160.94, a decline of 44.0%[29] Cash Flow - The company reported a net cash flow from operating activities of ¥209,549,867.80, which increased by 57.13% year-to-date[4] - Cash flow from operating activities generated ¥2,156,184,193.26, compared to ¥1,993,388,963.26 in the previous period, showing an increase of 8.2%[38] - Operating cash inflow totaled CNY 2,184,543,218.48, an increase of 8.1% from CNY 2,021,131,578.67 in the previous period[41] - Net cash flow from operating activities was CNY 209,549,867.80, compared to CNY 133,361,873.25, representing a 57.1% increase[41] - Cash inflow from financing activities totaled CNY 352,074,000.00, down from CNY 563,590,000.00, a decrease of 37.4%[44] - Net cash flow from financing activities was -CNY 43,062,707.58, an improvement from -CNY 92,354,132.77[44] Expenses - The company's revenue increased, leading to a rise in tax expenses by 36.48% to ¥11,537,065.63[10] - Sales expenses rose by 35.36% to ¥208,258,609.05 due to increased promotional efforts in the pharmaceutical sector[10] - R&D expenditure significantly decreased by 97.64% to ¥38,487.99, indicating reduced investment in research and development[10] - Financial expenses decreased by 40.93% to ¥69,648,211.06, attributed to lower interest expenses from reduced borrowings[10] - Other income surged by 488.38% to ¥12,223,305.67, primarily due to increased government subsidies recognized during the reporting period[10] - The company reported a 40.72% increase in taxes paid, totaling ¥86,387,792.49, reflecting higher revenue[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,071, with no preferred shareholders[11] - The largest shareholder, Que Wenbin, holds 28.93% of the shares, amounting to 539,639,999 shares, which are currently frozen[14] Restructuring and Risks - The company continues to operate during the restructuring process, as approved by the court, allowing ongoing business activities[18] - The company is under a "delisting risk warning" due to the ongoing restructuring process, with its stock still trading under the name "*ST 恒康"[18] - There is a risk of bankruptcy if the restructuring plan is not approved by the court, which could lead to the termination of the company's stock listing[18] - The company has appointed management from Beijing Junhe Law Firm and Gansu Jiezhao Law Firm to oversee the restructuring process[18] Other Financial Metrics - The company experienced a 45.84% increase in prepaid accounts due to unsettled purchases during the reporting period[7] - Cash outflow for the acquisition of fixed assets rose by 45.61% to ¥137,330,673.49, indicating increased capital expenditures[10] - Cash received from loans decreased by 46.73% to ¥220,000,000.00, reflecting a reduction in bank borrowings compared to the previous year[10] - The company's current assets totaled approximately CNY 1.32 billion, up from CNY 1.20 billion at the end of 2020, indicating an increase of around 10.2%[22] - The company's cash and cash equivalents reached approximately CNY 212.92 million, compared to CNY 171.65 million at the end of 2020, reflecting a growth of about 24.1%[22] - The accounts receivable increased to approximately CNY 634.03 million from CNY 568.75 million, marking an increase of about 11.5%[22]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,479,996,718.59, representing a 17.79% increase compared to CNY 1,256,467,897.88 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was a loss of CNY 49,109,956.06, which is a 2.79% increase in loss compared to a loss of CNY 47,776,912.52 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 27,855,153.20, showing a 47.21% improvement compared to a loss of CNY 52,765,252.67 in the same period last year[26]. - The net cash flow from operating activities was CNY 124,592,501.89, a decrease of 4.83% from CNY 130,916,111.00 in the previous year[26]. - The total assets at the end of the reporting period were CNY 4,894,329,740.83, reflecting a 1.53% increase from CNY 4,820,797,979.68 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company decreased by 36.69% to CNY 84,736,204.88 from CNY 133,846,160.94 at the end of the previous year[26]. - The basic and diluted earnings per share were both CNY -0.0263, a decrease of 2.73% compared to CNY -0.0256 in the same period last year[26]. - The weighted average return on net assets was -44.93%, a decline of 16.98% from -27.95% in the previous year[26]. Operational Developments - The company is currently undergoing a restructuring process, which carries the risk of potential bankruptcy if the restructuring fails[7]. - The company has established a professional hospital management team to enhance operational efficiency and service quality across its hospitals[41]. - The company has a strong market presence with a stable and professional sales team, focusing on academic promotion to enhance product brand influence[41]. - The company is committed to the dual-driven strategy of medical services and pharmaceutical manufacturing, with a focus on building regional medical centers[36]. - The company has been in the pharmaceutical industry for over 20 years, with its "Duyiwei" brand recognized as a famous trademark in China[36]. - The company has developed 36 types of pharmaceuticals, including 7 exclusive products nationwide and 12 products listed in the Chinese Pharmacopoeia (2020 edition)[36]. Financial Position and Liabilities - The company's debt-to-asset ratio stands at 97.72%, indicating a high level of debt risk[71]. - The company faces litigation with a total amount of approximately 1.3 billion yuan due to various disputes, contributing to its high debt levels[71]. - The company has entered a restructuring process, which carries the risk of potential bankruptcy if the restructuring fails[71]. - The company has not distributed cash dividends or bonus shares for the half-year period[78]. - The company has no stock incentive plans or employee stock ownership plans in place during the reporting period[79]. - The company is actively monitoring healthcare reform policies to mitigate potential operational impacts from policy changes[71]. Revenue Breakdown - Medical service revenue reached ¥1,255,075,775.96, representing 84.80% of total revenue, with a year-on-year increase of 15.01%[45]. - The total revenue from the pharmaceutical segment was ¥218,328,400.17, accounting for 14.75% of total revenue, with a year-on-year growth of 36.93%[45]. Investments and Subsidiaries - The company has invested ¥59,200,000 in the JF Huayue (Taizhou) Asset Management Center, holding a 10% share as a limited partner[62]. - The company also committed ¥63,800,000 to the JF Huacai (Taizhou) Asset Management Center, maintaining a 10% stake as a limited partner[65]. - The company reported a net profit of ¥30,967,515.16 from its subsidiary Kangxian Duyiwei Biopharmaceutical Co., Ltd., contributing over 10% to the overall net profit[59]. - The total assets of Kangxian Duyiwei Biopharmaceutical Co., Ltd. amounted to ¥790,555,231.87, with a revenue of ¥167,245,079.46[59]. - The total assets of the subsidiary Siyang People's Hospital Co., Ltd. were reported at ¥564,336,129.41, generating revenue of ¥308,918,338.27[59]. Shareholder Information - As of June 30, 2021, the controlling shareholder, Mr. Que Wenbin, had 638,509,999 shares frozen, accounting for 34.23% of the total share capital[113]. - The largest shareholder, Que Wenbin, holds 34.23% of the shares, totaling 638,509,999 shares, with a decrease of 154,000,000 shares during the reporting period[157]. - The second-largest shareholder, Sichuan Industrial Revitalization Development Investment Fund Co., Ltd., holds 6.03% of the shares, totaling 112,500,000 shares[157]. - The total number of shares pledged, marked, or frozen is 636,557,230 shares, primarily by Que Wenbin[157]. Legal and Compliance Issues - The company is involved in a significant lawsuit regarding a performance commitment dispute, with the plaintiff claiming a compensation of 91.03 million CNY for unmet performance targets in 2017[101]. - The company has been ordered to pay 22.96 million CNY in a ruling related to a share transfer dispute, which includes 12 million CNY in attorney fees and penalties[101]. - A court ruling has mandated the company to pay 92.77 million CNY related to a share transfer payment dispute[101]. - The company is currently appealing a court decision requiring it to pay approximately 387.92 million CNY in partnership equity acquisition payments and overdue interest[104]. - The company faces a claim of 43.66 million CNY in another partnership equity acquisition dispute, which is also under appeal[104]. - The company is involved in a loan contract dispute where it is required to repay 60 million CNY in principal and interest[107]. - The company has been ordered to pay 48 million CNY in a loan contract dispute, where it is held liable as a guarantor[107]. - The company is facing an arbitration claim for approximately 2.5 million EUR in intermediary service fees[111]. Environmental and Social Responsibility - The company has not faced any environmental penalties during the reporting period and adheres to relevant environmental laws[83]. - The company is committed to environmental protection, with all environmental facilities operating normally and meeting regulatory standards[85].

Business Model and Strategy - The company reported a significant shift from a single pharmaceutical manufacturing business to a dual-driven model focusing on medical services and pharmaceutical manufacturing, aligning with the "big health" industry strategy[21] - The company’s main business operations have expanded to include a variety of healthcare services, reflecting a strategic pivot in its business model[21] - The company aims to strengthen partnerships with top health service institutions and explore new high-end medical services[38] - The company is committed to deepening the development of unique Tibetan medicine products, aligning with national strategies for traditional medicine protection and innovation[39] - The company plans to implement the "hospital+" model to optimize resource allocation and address supply-demand issues in healthcare[108] - The company aims to increase drug sales revenue and brand influence through enhanced technology research and development and brand promotion efforts[132] - The company is exploring potential mergers and acquisitions to enhance its service offerings and market share[174] Financial Performance - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves for the fiscal year[6] - The company has received an unqualified audit report from Asia Pacific (Group) CPA, ensuring the accuracy and completeness of the financial statements[5] - The company has not disclosed specific future performance forecasts, emphasizing the uncertainty of achieving strategic goals due to market conditions[5] - The company’s financial report indicates a commitment to transparency and risk disclosure, with detailed descriptions of potential risks included in the report[5] - The company reported a basic and diluted earnings per share of -¥0.028, an improvement of 97.89% from -¥1.350 in 2019[23] - The company reported a net loss of 52.24 million CNY for 2020, with no cash dividends proposed for the year[116] - The company has not distributed cash dividends for the past three years due to continuous losses, with net losses of 2.52 billion CNY in 2019 and 1.42 billion CNY in 2018[119] - The company’s asset-liability ratio stands at 96.73%, indicating a high level of debt risk[112] Revenue and Expenses - The company's operating revenue for 2020 was ¥2,805,895,494.80, a decrease of 23.85% compared to ¥3,684,467,721.58 in 2019[23] - The company achieved total revenue of CNY 2.81 billion in 2020, a year-on-year decrease of 23.85%, with the medical services segment contributing CNY 2.37 billion, accounting for 84.62% of total revenue[56] - Service revenue accounted for 85.02% of total revenue, while industrial revenue made up 14.98%[64] - Medical service revenue was ¥2,374,437,844.47, down 2.32% from the previous year[64] - Gross profit margin for industrial revenue was 77.77%, while for service revenue it was 19.44%[68] - Sales expenses decreased by 8.95% to ¥223,099,998.35 due to pandemic-related restrictions[79] - Management expenses dropped by 43.31% to ¥337,739,590.33, primarily due to a reduced consolidation scope[79] - Financial expenses decreased by 64.53% to ¥139,922,838.34, attributed to lower interest expenses and exchange losses[79] Operational Metrics - The company operates 11 hospitals, including 1 tertiary hospital and 8 secondary or higher-level hospitals, focusing on regional medical centers[38] - The company expanded its academic promotion activities, conducting nearly 300 events in the second half of 2020 to enhance product recognition among doctors and patients[59] - The company added over 1,500 grassroots hospitals and more than 500 grade hospitals in 2020, effectively compensating for the decline in hospital medication usage due to the pandemic[59] - The hospital bed occupancy rate in China was 80.7% in 2019, indicating a high demand for inpatient services[45] - The number of patients served increased by 20% compared to the previous year, reaching 1.2 million patients[174] Market and Industry Trends - The healthcare industry in China is experiencing rapid growth, driven by an aging population and increasing healthcare awareness, with a significant rise in demand for medical services[40] - In 2019, the total healthcare expenditure in China reached CNY 65,195.9 billion, a year-on-year increase of 12.41%, with per capita healthcare expenditure at CNY 4,656.7[45] - The number of medical institutions in China increased to 1,007,545 by the end of 2019, with private hospitals growing by 6.90% year-on-year to 22,424[44] - The company is positioned to benefit from ongoing healthcare reforms aimed at addressing the challenges of accessibility and affordability in medical services[50] - The government has outlined a 10-year plan for healthcare reform, focusing on building a balanced and comprehensive medical insurance system by 2030[43] Risks and Challenges - The company is facing risks related to policy changes in the healthcare sector, which could impact its operations[112] - The company acknowledges the scarcity of high-quality medical talent as a significant risk factor affecting its service development[112] - The company is at risk of bankruptcy if its restructuring application is unsuccessful, which could lead to delisting[112] - The company faces a loan repayment obligation of ¥60 million to Huashang Bank, with ongoing litigation that may affect its financial position[154] - The company is involved in multiple lawsuits, including a claim for 91.03 million yuan related to performance compensation for 2017, which remains uncertain in its impact on future profits[145] Corporate Governance and Compliance - The company has established a comprehensive governance structure, with all board members present for the report's review, ensuring accountability[5] - The company has committed to ensuring the authenticity, accuracy, and completeness of restructuring application materials since January 20, 2016, and has strictly fulfilled this commitment[120] - The company has committed to strict compliance with relevant laws and regulations regarding share changes and has pledged to avoid any illegal trading activities[126] - The company has no reported penalties or rectifications during the reporting period, indicating compliance with regulations[155] Social Responsibility and Community Engagement - The company actively participated in COVID-19 pandemic response, deploying over 500 medical personnel to various prevention stations and screening over 300,000 individuals[192] - Total investment in poverty alleviation efforts amounted to approximately CNY 5.76 million, including CNY 5.23 million in funds and CNY 0.54 million in material donations[197] - The company helped 84 registered impoverished individuals to escape poverty during the reporting period[198] - The company provided free medical consultations and health education to rural communities through expert medical teams[197] - The company has maintained a commitment to environmental protection and improving product quality as part of its social responsibility efforts[192]